Albiglutide
Also referenced as: Tanzeum
An albumin-fused GLP-1 analogue with a history of approved diabetes treatment.
- Evidence grade
- AStrong Clinical Evidence
Strong Clinical Evidence
- Regulatory status
- FDA Approved for Specific Indication
Tanzeum was FDA-approved for adult type 2 diabetes but commercially discontinued; do not treat it as a currently marketed US option.
- Human data
- Yes
Registered clinical trials exist
- Last reviewed
- October 27, 2026
Overview
An albumin-fused GLP-1 analogue with a history of approved diabetes treatment.
Tanzeum was FDA-approved for adult type 2 diabetes but commercially discontinued; do not treat it as a currently marketed US option.
Historical approval and clinical evidence do not establish present commercial availability or an obesity indication.
Why It's Being Studied
- Type 2 diabetes
- Cardiovascular outcomes
Mechanism of Action
GLP-1 receptor activation supports glucose-dependent insulin secretion; albumin fusion prolongs exposure.
GLP-1 receptor activation supports glucose-dependent insulin secretion; albumin fusion prolongs exposure. Historical approval and clinical evidence do not establish present commercial availability or an obesity indication.
From molecular target to clinical evidence
Tap each stage to see what happens.
Background: Clinical Peptide Medicines
Clinical peptide medicines include endocrine treatments, antimicrobial drugs, receptor blockers and targeted diagnostic or cancer agents. They do not share one mechanism or one set of indications.
An approval belongs to a specific medicine and indication. A diagnostic tracer, an antibiotic and a hormone are not interchangeable wellness products; read each profile's own mechanism and prescribing source.
Research Areas & Routes Studied
- Type 2 diabetes
- Cardiovascular outcomes
- Subcutaneous historical approved medicine
Evidence Summary
HARMONY Outcomes demonstrated cardiovascular benefit in type 2 diabetes with established cardiovascular disease.
Higher tiers carry more weight. Filled tiers have evidence for Albiglutide; tap to read it.
- HARMONY Outcomes demonstrated cardiovascular benefit in type 2 diabetes with established cardiovascular disease.
2 cited sources.
- Prescribing label1
- Randomised controlled trial1
Human clinical evidence
- HARMONY Outcomes demonstrated cardiovascular benefit in type 2 diabetes with established cardiovascular disease.
Reported Adverse Events in Research
- Gastrointestinal intolerance, pancreatitis warnings and a thyroid C-cell tumor warning are important label considerations.
Limitations of Current Evidence
- Historical approval and clinical evidence do not establish present commercial availability or an obesity indication.
- Findings apply to the product, route and population studied; they do not establish benefits or safety for unrelated wellness uses or research-vial products.
How to Read This Research
- Is this a single molecule or a family of medicines?
- Is the use diagnostic, therapeutic or investigational?
- Does the quoted outcome match the exact product, formulation and population?
- Use the compound-specific mechanism above; this diagram describes drug development, not a shared biological pathway.
- Historical approval, present availability and off-label use are distinct questions.
- For radiopharmaceuticals and hospital medicines, specialist handling is part of the treatment context.
- Indication
- The condition and population for which a medicine is approved.
- Antagonist
- A compound that blocks activity at a receptor.
- Radiopharmaceutical
- A medicine containing a radioactive isotope for imaging or treatment.
Compare With Other Compounds
| Albiglutide | Trofinetide | |
|---|---|---|
| Evidence grade | A — Strong Clinical Evidence | B — Moderate Human Evidence |
| Regulatory status | FDA Approved for Specific Indication | FDA Approved for Specific Indication |
| Human data | Yes | Yes |
| Clinical trials | Registered trials exist | Registered trials exist |
| Research routes | Subcutaneous historical approved medicine | Oral approved medicine |
| Cited sources | 2 | 2 |
Frequently Asked Questions
Research References
- Prescribing label
Albiglutide — prescribing label
- Randomised controlled trial
HARMONY Outcomes